Artiva Biotherapeutics, Inc. (ARTV): Rasio kapitalisasi pasar marang pendapatan

Tandha merek Artiva (ARTV)

Artiva Biotherapeutics, Inc. (ARTV) develops innovative NK-cell-based therapies to combat tumors. Transparent leadership with a proven track record in commercializing cellular technologies ensures effective management following the IPO. The expansion strategy for allogeneic therapy is supported by strong capital and B2B relationships. The P/S multiple trend reflects the business valuation dynamics, where 211.40 represents the current level of the metric.

ARTV - Multiplikator P/S Artiva ing rentang 26.03.2025 - 09.05.2025

Rincian analitis perusahaan artivabio.com (ARTV)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:Artiva, ARTV
Sampel barang Artiva Biotherapeutics, Inc.

Exclusive technology rights when outsourcing production to Asia minimize the operational risks of Artiva Biotherapeutics, Inc. (ARTV). Current P/S levels on this chart reflect the market valuation of this model via the ratio of market capitalization to annual revenue. This multiple determines the fairness of the share price relative to the company's actual cash flow. Analyzing the trend of this indicator allows an investor to promptly detect whether the asset is overbought or identify an entry point when the business is undervalued.

Perusahaan pesaing

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd